You are here: Industry Insights > Imfinzi

News List

Imfinzi’s success in ES-SCLC not matched in combo with tremelimumab pharmaceutical-technology
March 18, 2020
AstraZeneca’s Imfinzi (durvalumab) plus standard of care (SoC) chemotherapies caused a sustained, clinically meaningful overall survival (OS) benefit in first line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Imfinzi cancer combo falls short in DANUBE trial pharmatimes
March 09, 2020
AstraZeneca has released an update from its Phase III DANUBE trial, assessing Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer.
Another Anti-PD-L(1) Monoclonal Antibody Filed the IND Application in China to Join the 40+ Applicants! Sales of Keytruda to Rank Second in the World in 2019 PharmaSources/1°C
November 14, 2019
MSD released the Q3 financial report on Oct. 29, 2019. Its figures, especially the figures of its oncology business, were no longer shining, with keywords including Keytruda, Gardasil 9, and China.
Imfinzi combination fails advanced lung cancer study europeanpharmaceuticalreview
August 23, 2019
A late-stage clinical trial for Imfinzi and an experimental treatment has not extended the lives of patients with advanced non-small cell lung cancer.
AstraZeneca’s Imfinzi fails to meet endpoint in Stage IV NSCLC pharmaceutical-technology
August 22, 2019
AstraZeneca has announced that Imfinzi (durvalumab), combined with tremelimumab, failed to achieve its primary endpoint in the Phase III NEPTUNE trial of patients with previously-untreated Stage IV non-small cell lung cancer (NSCLC).
FDA grants Orphan Drug Designation to Imfinzi for SCLC europeanpharmaceuticalreview
July 16, 2019
The FDA has announced Orphan Drug Designation for Imfinzi (durvalumab) to treat small cell lung cancer in combination with other therapies.
AstraZeneca’s Imfinzi tees up small cell lung cancer fight with Roche fiercepharma
July 04, 2019
After Imfinzi's key non-small cell lung cancer trial failure last year, AstraZeneca has some good news to report in lung cancer. But it's from the much smaller field of small cell lung cancer where Roche’s Tecentriq is a step ahead.
Imfinzi, Opdivo among latest SMC decisions pharmatimes
June 11, 2019
The Scottish Medicines Consortium (SMC) has announced its latest round of medicines for use by NHSScotland, publishing advice accepting five new medicines.
NICE recommends AstraZeneca’s Imfinzi through Cancer Drugs Fund By Allie Nawrat pharmaceutical-technology
April 03, 2019
The UK’s National Institute of Health and Care Excellence (NICE) has published its final guidance for AstraZeneca’s Imfinzi (durvalumab), in which it recommends the immunotherapy for use by the NHS through the Cancer Drugs Fund.
AZ' Imfinzi to be funded for NHS use via CDF pharmatimes
April 02, 2019
The National Institute for Health and Care Excellence (NICE) has recommended funding for use of AstraZeneca’s Imfinzi (durvalumab) on the NHS via the Cancer Drugs Fund.

Previous page 1 2 3 4 5 Next page